Dr. Shusterman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
255 VALLEY RIDGE RD
Haverford, PA 19041
Summary
- Dr. Neil Shusterman specializes in Nephrology and is based in Haverford, PA. He completed his medical degree at Sidney Kimmel Medical College at Thomas Jefferson University in 1978 and pursued his residency in Internal Medicine at Main Line Health System/Lankenau Medical Center. He further advanced his specialization with a Fellowship in Nephrology at University of Pennsylvania Health System from 1981-1983. Currently, Dr. Shusterman holds the position of Clinical Drug Development Consultant at NHSMD Clinical Consulting LLC. He is an established author, having published research in several esteemed medical journals including Dermatologic Surgery, Clinical Drug Investigation, Ann Intern Med, Expert Opinion on Drug Safety, and American Heart Journal.
Education & Training
University of Pennsylvania Health SystemFellowship, Nephrology, 1981 - 1983
Main Line Health System/Lankenau Medical CenterResidency, Internal Medicine, 1978 - 1981
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1978
Certifications & Licensure
PA State Medical License 1979 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Publications & Presentations
PubMed
- 29 citationsFenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients.Diane K. Jorkasky, Patricia R. Audet, Neil Shusterman, Bernard E. Ilson, Donald C. Dafoe
American Journal of Kidney Diseases. 1992-06-01 - 122 citationsWhat is the Cost of Nephrotoxicity Associated with AminoglycosidesJohn M. Eisenberg, Harris Koffer, Henry A. Glick, Margaret L. Connell, Larrye E. Loss
Annals of Internal Medicine. 1987-12-01 - 27 citationsCollagenase Clostridium Histolyticum for the Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite): A Randomized Trial.Neil S. Sadick, Mitchel P. Goldman, Genzhou Liu, Neil H. Shusterman, Michael McLane
Dermatologic Surgery. 2019-08-01
Authored Content
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure — NEJMMay 1996
Press Mentions
Palladio Biosciences Announces First Patient Dosed with Lixivaptan in the ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued from Treatment with Tolvaptan Due to Liver ToxicityNovember 17th, 2020- Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient Who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 MeetingOctober 20th, 2020
Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief Medical Officer (CMO)January 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
